Summary of the Conference Call on Preclinical CRO Industry Industry Overview - The preclinical Contract Research Organization (CRO) sector is experiencing a significant surge in orders, with a full recovery expected by Q4 2025. Orders are projected to increase by tens of percentage points year-on-year in H1 2026, potentially doubling the order value due to both volume and price increases [1][2]. Core Insights and Arguments - **Service Price Recovery**: Rapid recovery in service prices has been noted, particularly in the safety evaluation sector, where discounts have narrowed from 50% to no discount, resulting in year-on-year price increases of several tens of percentage points. This price increase is expected to translate directly into profits [1][2]. - **Monkey Resource Supply Shortage**: A critical factor driving the increase in service prices is the shortage of monkey resources, exacerbated by slow import approval processes. This shortage has led to a dramatic rise in monkey prices, which in turn has pushed up service fees [3]. - **BD Transaction Activity**: The active business development (BD) transactions are concentrating research and development investments in the preclinical phase. High-value orders are expected to be fully reflected in financial reports by Q3 2026, with net profits anticipated to return to 2021 peak levels by Q1 2027 [1][4]. Future Outlook - **Order Sustainability**: There are no immediate concerns regarding order sustainability. Orders are expected to show strong performance in Q1 and Q2 of 2026, with projected year-on-year growth of several tens of percentage points. The overall order amount may double due to the combined effect of increased order volume and service price hikes [4]. - **Profit Margin Impact**: The rapid increase in order prices is expected to significantly enhance profit margins for related companies. The price improvement began in Q3 2025, with discounts narrowing from 50-60% to 80-90%. This price increase is anticipated to be reflected in financial statements starting Q3 2026, with some companies potentially reaching net profit levels close to the peak of 2021 by Q1 2027 [5][6]. Key Companies to Watch - **InnoCare Pharma**: Recommended due to its low correlation with the domestic market and strong order certainty in Q1 and Q2 of 2026. Its smaller market capitalization provides significant upside potential [7]. - **Zhaoyan New Drug**: Despite facing a reduction event, it presents a good entry point. The profit levels in 2027 are expected to match or exceed those of 2021, with considerable room for growth compared to previous peaks [7]. - **Medpace**: As a leading integrated preclinical service provider, it is currently benefiting from the focus on safety evaluation. As the industry continues to improve, its front-end services are expected to gain traction, revealing its performance elasticity [7]. Overall Market Trend - The current market situation is just the beginning, driven by improved BD conditions for innovative drugs in 2025. Although there have been significant stock adjustments due to rising monkey prices and corrections in the innovative drug sector, the current position offers a favorable entry point for investors. Continued healthy development of the Chinese innovative drug industry is expected to benefit domestic CRO companies, with potential for greater valuation expansion if orders remain strong in the second half of the year [8][9].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. 百奧賽圖（北京）醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2315） 海外監管公告 本公告乃百奧賽圖（北京）醫藥科技股份有限公司（「本公司」）根據香港聯合交易所 有限公司證券上市規則第13.10B條的規定刊發。 茲載列本公司於上海證券交易所網站刊發的以下公告，僅供參閱。 1 1. 百奧賽圖（北京）醫藥科技股份有限公司2025年年度報告 2. 百奧賽圖（北京）醫藥科技股份有限公司2025年年度報告摘要 3. 百奧賽圖（北京）醫藥科技股份有限公司2025年度環境、社會和公司治理 (ESG)報告 4. 百奧賽圖（北京）醫藥科技股份有限公司2025年度環境、社會和公司治理 (ESG)報告摘要 5. 百奧賽圖（北京）醫藥科技股份有限公司2025年度利潤分配方案公告 6. 百奧賽圖（北京 ...

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The clinical research organization (CRO) sector is experiencing a significant recovery, with new orders and backlog orders showing rapid growth. Notable companies like Medpace and Yino Science have reported substantial increases in new orders and revenue [4][14] - The price of experimental monkeys, a key material for preclinical research, has surged, indicating strong demand in the domestic innovative drug industry. The price has risen to over 130,000 yuan per monkey, up from approximately 90,000 yuan in mid-2025 [5][15] - The report emphasizes the continued recommendation of the domestic preclinical CRO sector, anticipating further acceleration in order growth [5][14] Summary by Sections Section 1: Order Growth in Preclinical CRO - Medpace signed new orders worth approximately 1.6 billion yuan in 2025, a year-on-year increase of about 45%, with revenue also growing by 12% [14][15] - Yino Science reported new orders of 1.135 billion yuan, up 38.62% year-on-year, with a backlog of 1.248 billion yuan, reflecting a 28.23% increase [14][15] - The backlog for Aopumai's subsidiary, Pengli Biology, reached 252 million yuan, a 37.68% increase year-on-year [14][15] Section 2: Market Performance - In the first week of March 2026, the pharmaceutical and biological sector fell by 2.78%, underperforming the CSI 300 index by 1.71 percentage points, ranking 17th among 31 sub-industries [6][17] - The in vitro diagnostics sector showed the highest increase, while the medical research outsourcing sector experienced the largest decline, down 4.99% [20][21] Section 3: Recommendations - The report maintains a positive outlook on the innovative drug and its supply chain, including CXO and research services, as well as emerging industries like AI and brain-machine interfaces [7] - Monthly recommendations include companies such as WuXi AppTec, CSPC Pharmaceutical Group, and Innovent Biologics, while weekly recommendations feature Aopumai, Medpace, and others [7]

Acquisitions - Charles River announced the strategic acquisition of K.F. (Cambodia) Ltd. for approximately $510 million, expected to complete in Q1 2026, to self-supply most annual NHP needs[4] - The company will also acquire the remaining 79% of PathoQuest for about €51.60 million (approximately $60 million), expected to contribute $15-20 million in revenue in 2026[4] Supply Chain and Technology Enhancement - The acquisition of K.F. will aid in vertical integration amid global NHP resource constraints, enhancing DSA business stability and cost control[5] - PathoQuest's NGS quality control technology will improve NAMs and bioproduct quality control, increasing the proportion of high-value services[5] DSA Demand Recovery - DSA net book-to-bill ratio reached 1.1x in Q4 2025, up from 0.8x in Q2-Q3 2025, indicating a recovery driven by small and medium biotech demand and growth in large pharma orders[6] - This recovery signals a gradual bottoming out of preclinical demand[6] 2026 Performance Outlook - The company is cautiously optimistic for 2026, expecting organic revenue growth to be at least flat, with DSA business resuming organic growth in H2 2026[6] - Forex is expected to contribute 100-150 basis points to revenue growth[6] Investment Recommendations - Long-term positive outlook on pharmaceutical growth, with a focus on domestic companies such as WuXi AppTec and Pharmaron[7] - Suggested companies to watch include WuXi AppTec, Pharmaron, JOINN Laboratories, and others[7] Risk Factors - Risks include a weaker-than-expected global biotech financing environment and challenges in NHP supply chain recovery[7] - Potential risks related to acquisition integration and project execution[7]

Fundraising Performance - In December 2025, 18 new stocks were listed on the A-share market, raising a total of 31.41 billion yuan, marking the highest monthly fundraising since September 2023[4] - For the entire year of 2025, a total of 116 new stocks were listed, raising 131.77 billion yuan, which represents increases of 16% and 96% compared to the same period in 2024, respectively[5] - The monthly fundraising amount in December 2025 exceeded 30 billion yuan, driven by several large projects including Moer Thread and Muxi Co., which raised over 4 billion yuan each[3] Initial Performance of New Stocks - In December 2025, 14 out of 15 new stocks listed on the Shanghai and Shenzhen markets adopted offline issuance, with an average first-day increase of 249%, continuing the upward trend from November[11] - The average first-day increase for new stocks on the Sci-Tech Innovation Board exceeded 300%, with Moer Thread and Muxi Co. seeing increases of over 600% and 400%, respectively[14] - The main board saw an average first-day increase of 200% for its four new stocks, with China Uranium Industry leading at 269%[14] Subscription Returns - In December 2025, the estimated returns for A/B class accounts from new stock subscriptions were 5.48 million yuan and 2.87 million yuan, respectively, marking the highest monthly returns of the year[21] - The returns from the Sci-Tech Innovation Board's new stocks contributed significantly, with the average return for A/B class accounts being 4.71 million yuan and 2.13 million yuan, respectively[21] Investment Strategy and Risks - The current optimal strategy is to participate in low-priced, small-cap new stocks with expected first-day increases exceeding expectations, as well as large-cap stocks with significant offline allocation[22] - Risks include an increased rate of new stock price declines and a potential decrease in subscription success rates, which could impact overall returns[3]

Group 1 - The core viewpoint of the news is that Baiaosaitu has successfully listed its H-shares on the Hong Kong Stock Exchange and has been included in the Hong Kong Stock Connect program, allowing eligible investors from mainland China to invest directly in its H-shares [1][3] - Following this announcement, Baiaosaitu's H-shares surged by 22.23% to HKD 35.08 per share, while its A-shares increased by 3.42% to CNY 52.6 per share, indicating strong market reaction [1] - The inclusion in the Hong Kong Stock Connect is seen as a significant milestone for the company, enhancing its capital accessibility, market recognition, and long-term investment value [1][3] Group 2 - Baiaosaitu, established in 2009, operates as a preclinical CRO and biopharmaceutical company, providing innovative animal models and preclinical drug development services based on its proprietary gene editing technology [2] - The company has developed a comprehensive platform for drug discovery and development, including the RenMice platform, which targets over a thousand potential drug targets [2] - Baiaosaitu has signed approximately 280 drug cooperation development, licensing, and transfer agreements, establishing a leading global repository of humanized mouse models and offering full-chain capabilities in preclinical pharmacology and efficacy research [3] Group 3 - The company aims to leverage the synergy between its A-share and H-share platforms to enhance its technological platform transformation, global business expansion, and long-term strategic implementation [3] - Baiaosaitu is committed to maintaining a technology innovation-driven approach, deepening its global collaboration network, and improving operational quality and communication with the capital market [3] - The company positions itself as a "global source of new drugs," contributing long-term value to the high-quality development of China's biopharmaceutical industry and global innovation [3]

Core Viewpoint - The company Bai'ao Saituo has successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, leveraging its "Thousand Mice and Ten Thousand Antibodies" plan and RenMice human antibody platform, but faces multiple risks including reliance on cost-cutting for profitability, high proportion of related-party transactions, patent infringement lawsuits, and significant unremedied losses [1][4]. Group 1: Financial Performance and Cost Management - From 2022 to 2024, Bai'ao Saituo's operating revenue steadily increased, with net profit turning from a loss of 602 million yuan to a profit of 33.54 million yuan, and achieving a net profit of 114 million yuan in the first three quarters of this year [6]. - However, R&D expenses significantly decreased from 699 million yuan to 324 million yuan, and the total number of R&D personnel dropped from 627 to 337, with dedicated R&D staff reduced from 58 to 5 [6]. - The revenue growth of 446 million yuan during the same period contrasts with a decline in R&D expenses of 375 million yuan, raising concerns about whether profitability improvements stem from cost-cutting rather than genuine business growth [6]. Group 2: Related-Party Transactions and Patent Litigation - The antibody development business, a key growth area for Bai'ao Saituo, has a compound annual growth rate of 58.26% from 2022 to 2024, with a gross margin exceeding 80% [7]. - Nearly 30% of the revenue in this segment comes from related parties, specifically from joint ventures such as Doma Pharmaceutical and its subsidiary, contributing a total of 170 million yuan, which accounts for 27.43% of total antibody development revenue [7]. - The core technology platform RenMice faces intellectual property risks, as a lawsuit was filed by He Bo Pharmaceutical in September 2024, alleging patent infringement, which could undermine market confidence in the company's technological independence [7]. Group 3: Unremedied Losses and Debt Concerns - As of the end of 2024, Bai'ao Saituo has accumulated unremedied losses of 1.754 billion yuan, with the company acknowledging the risk of returning to losses if R&D investments remain high or revenue growth does not meet expectations [8]. - The controlling shareholders, Shen Yuele and his wife, face significant debt obligations, needing to repay approximately 129 million yuan from 2025 to 2028, primarily relying on the liquidation of their H-shares in the company [8]. - The total compensation for the company's directors, supervisors, and key technical personnel from 2022 to 2024 reached 61.6072 million yuan, maintaining a high level despite the company's losses, which has raised inquiries from the stock exchange [8].

Core Viewpoint - Bai'ao Saitou (Beijing) Pharmaceutical Technology Co., Ltd. is planning to raise approximately 1.18 billion yuan through its initial public offering (IPO) on the Sci-Tech Innovation Board, with the funds allocated for various drug development projects and working capital [2]. Group 1: Company Overview - Bai'ao Saitou was established in 2009 and operates as a preclinical Contract Research Organization (CRO) and biotechnology company [2]. - As of the signing date of the prospectus, the company is jointly controlled by Shen Yulei and Ni Jian, who hold a combined 26.8665% voting rights and are husband and wife [2]. Group 2: IPO Details - The company plans to issue 47.5 million new shares at an offering price of 26.68 yuan per share, aiming to raise a total of approximately 1.27 billion yuan [2]. - After deducting estimated issuance costs of about 122.95 million yuan (excluding tax), the net proceeds from the IPO are expected to be around 1.14 billion yuan [2]. - The funds will be used for the construction of a drug early-stage research and development service platform, antibody drug research and evaluation projects, preclinical research projects, and to supplement working capital [2].

Group 1 - The core point of the article is the announcement of a new IPO application for the company Bai Ao Sai Tu, which is a preclinical CRO and biotechnology firm [1] - There are no new stock listings today, indicating a focus solely on the IPO application [1] - Bai Ao Sai Tu operates within the clinical research organization (CRO) sector, which is critical for supporting biotechnology and pharmaceutical companies [1]

Core Viewpoint - Baiaosaitu (Beijing) Pharmaceutical Technology Co., Ltd. is focused on innovative drug development and aims to enhance its capabilities through an IPO on the Sci-Tech Innovation Board, raising approximately 1.185 billion RMB for various projects [9][10][35]. Company Overview - Baiaosaitu is an innovative preclinical CRO and biotechnology company established in 2009, specializing in gene editing technology and providing various preclinical drug development services [12]. - The company has developed four major technology platforms: gene-edited model animal preparation, innovative model animal breeding and supply, preclinical pharmacology and efficacy evaluation, and antibody drug discovery [7][12]. Business Model and Services - The company addresses two core challenges in antibody drug development: obtaining high-quality antibody molecules and the lack of precise evaluation models [8]. - Baiaosaitu has created a comprehensive human antibody library and a humanized mouse library, enabling the discovery of antibody candidates against over 1,000 potential drug targets [8][16]. - The company has established partnerships with top global pharmaceutical companies, enhancing its credibility and accelerating its international business expansion [8][14]. Financial Overview - The company expects to raise 1.185 billion RMB through its IPO, which will be used for upgrading early drug development service platforms, antibody drug research, and enhancing preclinical research projects [9][35]. - The company's main business revenue has shown a compound annual growth rate of 35.56% over the past three years, with revenues of approximately 533.36 million RMB, 716.40 million RMB, and 980.07 million RMB in recent years [22]. Future Development Plans - The company plans to continue promoting its "Thousand Mice and Ten Thousand Antibodies" initiative, aiming to discover novel antibody candidates for external collaboration or internal development [24]. - Baiaosaitu intends to expand its preclinical product and service offerings, particularly in oncology, autoimmune diseases, cardiovascular, metabolic, and neurological disorders [24][25]. - The company aims to establish extensive partnerships with leading pharmaceutical and biotechnology companies both domestically and internationally [25]. Competitive Advantages - The company possesses leading gene editing technology, a comprehensive range of model animals, and a significant first-mover advantage in antibody development [27]. - The unique "Thousand Mice and Ten Thousand Antibodies" plan provides flexibility in research, collaboration, and business models, enhancing its competitive edge [27]. Regulatory and Market Position - Baiaosaitu has received AAALAC certification, ensuring compliance with international standards for laboratory animal care [20]. - The company meets the listing standards for the Sci-Tech Innovation Board, with an expected market value of no less than 3 billion RMB and recent annual revenue exceeding 300 million RMB [32].